Compare Amgen, Inc. (AMGN) vs 8x8 Inc (EGHT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs 8x8 Inc — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while 8x8 Inc trades at $2.02 (market cap $290.65M). The key difference: Amgen, Inc. is far larger — about 674.8× 8x8 Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| AMGN | EGHT | |
|---|---|---|
Market Cap | $196.12B | $290.65M |
Sector | Health | Technology |
52-Week High | $388.16 | $2.76 |
52-Week Low | $271.18 | $1.59 |
Enterprise Value | $241.41B | $568.33M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
EGHT trades at $2.05, down 0.49% today, with a bullish technical signal from moving averages. The company shows strong revenue growth with Q4 2026 earnings beating estimates at $0.11 per share versus $0.07 expected. Recent positive news includes AI product launches and industry recognition, though profitability remains weak with a net margin of just 0.22% and negative retained earnings of -$887.72 million.
Outlook is mixed with analyst consensus leaning neutral (39% buy, 43% hold). Key opportunities include AI-driven product expansion and consistent earnings beats, while risks involve high debt levels, thin margins, and competitive pressures in the CPaaS space. The stock's high P/E ratio of 205 suggests growth expectations are priced in.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →
